Navigation Links
Neurelis Announces Positive Results from Phase 1 Pharmacokinetic Study of NRL-01 (intranasal diazepam)
Date:6/14/2011

SAN DIEGO, June 14, 2011 /PRNewswire/ -- Neurelis, Inc. today announced the results of a randomized crossover study in healthy volunteers assessing diazepam pharmacokinetics and bioavailability after administration of their proprietary intranasal diazepam formulations and intravenous injection. The study was designed and conducted in collaboration with investigators at the University of Minnesota. Comparative analysis of the lead intranasal formulation, NRL-1, revealed promising pharmacokinetic results.  In its evaluation of a 10mg diazepam dose in the NRL-1 intranasal solution formulation, the study showed the following:

  • NRL-1 is well-tolerated, with only mild adverse events reported
  • Similar bioavailability to intravenous administration of diazepam (100% vs. 96%)
  • Tmax of 1.5 hours.
  • Cmax of approximately 272 ng/ml.
  • These values are comparable to those reported in the literature for Diastat® (rectal diazepam gel) at equivalent doses.  Diastat is the only approved therapy for the at home treatment of acute repetitive seizures.

  • "The results from this pilot study are very encouraging," commented Jim Cloyd, PharmD, University of Minnesota professor and principal investigator of the study, "The only approved drug to treat breakthrough seizures outside the hospital is diazepam rectal gel, a therapy that many older children and adults decline to use.  The ability to quickly and efficiently deliver, via intranasal administration, clinically relevant diazepam levels offers a more acceptable method of rescue therapy. The bioavailability and relatively low variability in exposure of the intranasal diazepam solution exceeded our expectations.  We look forward to further development of this important therapy."

    Dr. Wheless, Director of the LeBonheur Comprehensive Epilepsy Program at the University of Tennessee added, "Currently, the many patients with epilepsy do not have a viable option to help
    '/>"/>

    SOURCE Neurelis, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Neurelis Announces Completion of Dosing in Study of Intranasal Diazepam
    2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
    6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
    9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
    10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
    11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... Md. , Aug. 28, 2014 ... of novel anti-infective biologic and drug candidates targeting ... and FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced ... phase of cGMP manufacturing of SYN-004, Synthetic Biologics, ... Clostridium difficile ( C. difficile ) ...
    (Date:8/28/2014)... 28, 2014 Today is the official launch ... higher education, student and pharmaceutical organizations that will work ... ADHD prescription stimulant medication. The Coalition will initially focus ... reported rates of nonmedical use vary, a 2013 study ... 1 of college students reported nonmedical use of ...
    (Date:8/27/2014)... 27, 2014 TWi Pharmaceuticals, Inc. (4180.TT) today ... the United States Food and Drug Administration (FDA) ... megestrol acetate 125mg/ml oral suspension, the generic equivalent ... first-to-file and under Hatch Waxman rules, it will ...  TWi has completed the pre-launch preparation of the ...
    Breaking Medicine Technology:Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 4Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 5New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 2New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 3New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 4New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 5New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 6TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2
    ... -- American Oriental Bioengineering, Inc. (NYSE: AOB ) ... (the "NYSE") has notified the Company that it is not ... to timely file its Annual Report on Form 10-K with ... rules, when a Company does not comply with annual report ...
    ...  In conjunction with its first quarter 2012 earnings release (expected to be ... CVD ) is pleased to invite you to listen to its ... on Thursday, May 3, 2012 at 9:00 a.m. ET. , ... and Slide Presentation , , , , When: , , , ...
    Cached Medicine Technology:American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2
    (Date:8/28/2014)... 28, 2014 Vitals, a recognized and trusted ... Fabi of Cosmetic Laser Dermatology one of their Top ... of patients to share their doctor experiences and rate their ... time, and follow-ups. The Vitals Top 10 Doctor recognition means ... was ranked one of the highest by patients. , “I’m ...
    (Date:8/28/2014)... 2014 Altec Products, Inc., a ... announced today that they have been awarded the ... of the International Association of Microsoft Channel Partners ... founded in 1994, providing Microsoft Partners with a ... community at large while facilitating mutual growth and ...
    (Date:8/28/2014)... (PRWEB) August 28, 2014 The Baltimore ... web design firms in Baltimore and awarded The ... on 2013 revenue from Web design, The Canton Group ... The Canton Group’s clients include Fortune 1000, higher education, ... organizations. The Canton Group specializes in web design and ...
    (Date:8/28/2014)... 28, 2014 Postcard-worthy views, star-laden skies, ... glamping by the beach in your own private bungalow ... Palmar at the Islands of Loreto. , The newest ... unforgettable experience in paradise with its romantic Honeymoon package, ... 2014. , “Villa del Palmar at the Islands of ...
    (Date:8/28/2014)... Labor Day weekend typically conjures up images ... glorious glimpses of summer. However, more of Dr. ... their long weekend recovering from a quick cosmetic procedure. ... plastic and reconstructive surgeon based out of Newport Beach, ... their holiday weekends to do something for themselves. ...
    Breaking Medicine News(10 mins):Health News:Dr. Sabrina Fabi of Cosmetic Laser Dermatology Recognized as Vitals Top 10 Doctor 2Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 2Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 3Health News:The Canton Group is Recognized by the Baltimore Business Journal as the Largest Web Design Firm in Baltimore 2Health News:Honeymoon in Paradise at Villa del Palmar at the Islands of Loreto 2Health News:Honeymoon in Paradise at Villa del Palmar at the Islands of Loreto 3Health News:Honeymoon in Paradise at Villa del Palmar at the Islands of Loreto 4Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 2Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 3Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 4
    ... New research challenges the previously held belief that infants' ... new study finds the brain's left hemisphere plays the ... immediately after birth. ,Researchers are using functional ... activity in response to speech. They say this is ...
    ... try to avoid getting it, but researchers say common cold ... genetically engineer the common cold virus so that //it kills ... They did this by modifying one gene, so the virus ... the activity of another gene to ensure that the virus ...
    ... Government guidelines on the treatment of asthma have long ... for people with persistent forms of the condition.But reports ... people -- including parents of asthmatic children -- to ... growth retardation in children, weak bones in children and ...
    ... therapeutic option for patients with complicated type 1 diabetes, ... // Now, a new study finds ... worse survival than patients on the transplant waiting list ... Association supports a pancreatic transplant for patients who have ...
    ... a vaccine made from the common cold virus may induce ... the Centers for Disease Control and Prevention injected six monkeys ... parts of the SARS coronavirus. A new form of the ... were given a second vaccine 28 days later, and researchers ...
    ... women with diabetes have a higher risk of depression., ... 60 and 79. The participants were divided //into two ... the second included those without diabetes. Women who did ... groups, based on their levels of insulin resistance. ...
    Cached Medicine News:Health News:New Technique to Study Infants Brain. 2Health News:Benefits and Risks of Asthma Treatment Questioned 2Health News:Pancreas Transplant for Diabetics 2
    ... GV is a sterile, non-pyrogenic, transparent ... noninflammatory, high molecular weight (average = ... hyaluronate. Healon GV contains 14 mg/mL ... a physiological sodium chloride-phosphate buffer (pH ...
    ... PROVISC ophthalmic viscosurgical device ... is characterized by high molecular ... surface tension. It provides excellent ... and is easily removed. It ...
    ... a product comes along that forever raises ... category. The new StealthStation TREON plus Treatment ... Built on the phenomenal success of the ... system in the worldthe new TREON plus ...
    ... the DigiCat Imager ("DCI") to provide rapid, ... The DCI can measure the cataract and ... objective, appropriate and timely surgical decision can ... technology is especially useful in todays healthcare ...
    Medicine Products: